Calcium signaling dysregulation represents a fundamental pathological mechanism across multiple neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS)[1][2][3]. Normal calcium homeostasis is essential for neuronal survival, synaptic function, and cellular signaling. Disruption of calcium regulation leads to excitotoxicity, mitochondrial dysfunction, and neuronal death.
The therapeutic targeting of calcium pathways has garnered significant investment attention, though the field remains underfunded relative to amyloid and tau approaches. This investment landscape analysis examines the current pipeline, key players, and gaps in calcium-targeted therapies for neurodegeneration.
Voltage-gated calcium channel (VGCC) modulators represent one of the most advanced approaches to calcium dysregulation therapy:
| Drug/Program | Company | Target | Stage | Indication |
|---|---|---|---|---|
| L-type modulators | Various | L-type Ca2+ channel | Preclinical | Research |
| Nimodipine (repurposed) | Various | L-type VGCC | Phase 2 | AD |
| Ziconotide derivatives | Jazz Pharmaceuticals | N-type VGCC | Preclinical | ALS |
SOCE blockade addresses calcium dysregulation at the ER-plasma membrane interface:
| Drug/Program | Company | Target | Stage | Indication |
|---|---|---|---|---|
| GSK-3008308 | GSK | STIM1/ORAI1 | Phase 1 | AD |
| RP4014 | Ripple Therapeutics | ORAI1 | Preclinical | ALS |
Targeting mitochondrial calcium overload is a promising approach:
| Drug/Program | Company | Target | Stage | Indication |
|---|---|---|---|---|
| MCU inhibitors | Various | MCU | Preclinical | PD, ALS |
| MCU modulators | Academic | Mitochondrial Ca2+ | Research |
Calpain overactivation leads to pathological protein degradation:
| Drug/Program | Company | Target | Stage | Indication |
|---|---|---|---|---|
| A-705253 | Abbott | Calpain I/II | Phase 1 | Stroke, AD |
| MDL-28170 | Various | Calpain | Preclinical | AD |
Enhancing endogenous calcium buffering is an emerging approach:
| Approach | Target | Stage | Indication |
|---|---|---|---|
| Parvalbumin overexpression | Calcium binding | Preclinical | AD |
| Calbindin upregulation | Calcium buffering | Research | PD |
Analysis of clinical trials targeting calcium pathways in neurodegeneration:
This distribution indicates an early-stage pipeline with significant opportunity for advancement.
Mitochondrial Calcium Uniporter (MCU) Modulators
SOCE Inhibitors
Calpain Inhibitors
Combination Therapies
Berridge MJ. Calcium signalling and Alzheimer's disease. Neurochemical Research. 2011;36(7):1149-1156. https://pubmed.ncbi.nlm.nih.gov/21184270/. 2011. ↩︎
Surmeier DJ, Schumacker PT. Calcium, ageing, and neuronal vulnerability in Parkinson's disease. Lancet Neurology. 2013;12(10):953-963. https://pubmed.ncbi.nlm.nih.gov/24012373/. 2013. ↩︎
Robustelli AL, et al. Calcium dysregulation in ALS: mechanisms and therapeutic approaches. Brain Research. 2020;1747:147050. https://pubmed.ncbi.nlm.nih.gov/32387262/. 2020. ↩︎